Despite constituting only approximately 6% of the total tumor cells, this population exhibited upregulation of MHC-II genes and actively interacted with immune cells, such as CD4+ T cells, prevalent in TNBC patients who have better survival outcomes, i.e., the nonTD patient group. This evidence concerns the gene CD4 and neoplasm.